Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

被引:57
作者
Bar-Or, Amit [1 ]
Wiendl, Heinz [2 ]
Miller, Barry [3 ]
Benamor, Myriam [4 ]
Truffinet, Philippe [4 ]
Church, Meg [5 ]
Menguy-Vacheron, Francoise [4 ]
机构
[1] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[2] Univ Munster, Munster, Germany
[3] Sanofi, Bridgewater, NJ USA
[4] Genzyme A Sanofi Co, Chilly Mazarin, France
[5] Fishawack Commun Inc, Horsham, PA USA
关键词
D O I
10.1212/NXI.0000000000000070
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To evaluate immune responses to neoantigen and recall antigens in healthy subjects treated with teriflunomide. Methods: This was a randomized, double-blind, placebo-controlled study. Subjects received oral teriflunomide (70 mg once daily for 5 days followed by 14 mg once daily for 25 days) or placebo for 30 days. Antibody responses were evaluated following rabies vaccination (neoantigen) applied at days 5, 12, and 31 of the treatment period. Occurrence of delayed-type hypersensitivity (DTH) to Candida albicans, Trichophyton, and tuberculin (recall antigens) was assessed before and at the end of treatment to investigate cellular memory response. Safety and pharmacokinetics were evaluated. Results: Forty-six randomized subjects were treated (teriflunomide, n = 23; placebo, n = 23) and completed the rabies vaccination. Geometric mean titers for rabies antibodies were lower with teriflunomide at days 31 and 38 than with placebo. However, all subjects achieved sufficient seroprotection following rabies vaccination (titers well above the 0.5 IU/mL threshold). Overall, the DTH response to recall antigens in the teriflunomide group did not notably differ from responses in the placebo group. Conclusions: Following vaccination, geometric mean titers for rabies antibodies were lower with teriflunomide than with placebo. However, teriflunomide did not limit the ability to achieve seroprotective titers against this neoantigen. Evaluation of DTH showed that teriflunomide had no adverse impact on the cellular memory response to recall antigens. Classification of evidence: This study provides Class II evidence that in normal subjects treated with teriflunomide, antibody titer responses to rabies vaccination are lower than with placebo but sufficient for seroprotection.
引用
收藏
页数:8
相关论文
共 29 条
[1]  
AUBAGIO, 2013, AUBAGIO SUMM PROD CH
[2]  
AUBAGIO prescribing information, 2012, AUBAGIO PRESCR INF
[3]   Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals [J].
Azzoni, Livio ;
Foulkes, Andrea S. ;
Firnhaber, Cynthia ;
Yin, Xiangfan ;
Xiang, Zhi Q. ;
Li, Yan ;
Stevens, Wendy ;
Gross, Robert ;
Ertl, Hildegund C. J. ;
Sanne, Ian ;
Montaner, Luis J. .
AIDS, 2012, 26 (11) :1355-1362
[4]   Teriflunomide and Its Mechanism of Action in Multiple Sclerosis [J].
Bar-Or, Amit ;
Pachner, Andrew ;
Menguy-Vacheron, Francoise ;
Kaplan, Johanne ;
Wiendl, Heinz .
DRUGS, 2014, 74 (06) :659-674
[5]   Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis [J].
Bar-Or, Amit ;
Freedman, Mark S. ;
Kremenchutzky, Marcelo ;
Menguy-Vacheron, Francoise ;
Bauer, Deborah ;
Jodl, Stefan ;
Truffinet, Philippe ;
Benamor, Myriam ;
Chambers, Scott ;
O'Connor, Paul W. .
NEUROLOGY, 2013, 81 (06) :552-558
[6]   Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial [J].
Bingham, Clifton O., III ;
Looney, R. John ;
Deodhar, Atul ;
Halsey, Neal ;
Greenwald, Maria ;
Codding, Christine ;
Trzaskoma, Benjamin ;
Martin, Flavius ;
Agarwal, Sunil ;
Kelman, Ariella .
ARTHRITIS AND RHEUMATISM, 2010, 62 (01) :64-74
[7]   Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study [J].
Boulton, Craig ;
Meiser, Karin ;
David, Olivier J. ;
Schmouder, Robert .
JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (12) :1879-1890
[8]   Resetting the adaptive immune system after autologous stem cell transplantation: Lessons from responses to vaccines [J].
Brinkman, D. M. C. ;
Zijde, C. M. Jol-Van der ;
ten Dam, M. M. ;
Boekhorst, P. A. W. Te ;
ten Cate, R. ;
Wulffraat, N. M. ;
Hintzen, R. Q. ;
Vossen, J. M. ;
van Tol, M. J. D. .
JOURNAL OF CLINICAL IMMUNOLOGY, 2007, 27 (06) :647-658
[9]   Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man [J].
Brinkman, DMC ;
Jol-Van der Zijde, CM ;
Ten Dam, MM ;
Vossen, JM ;
Osterhaus, ADME ;
Kroon, FP ;
Van Tol, MJD .
JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (06) :528-538
[10]   Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide [J].
Bruneau, JM ;
Yea, CM ;
Spinella-Jaegle, S ;
Fudali, C ;
Woodward, K ;
Robson, PA ;
Sautès, C ;
Westwood, R ;
Kuo, EA ;
Williamson, RA ;
Ruuth, E .
BIOCHEMICAL JOURNAL, 1998, 336 :299-303